Acute pancreatitis market seen reaching $8.55 billion by 2030

The Business Research Company projects steady growth in the acute pancreatitis market as gallstone disease, alcohol-related cases and healthcare spending rise. The market is forecast to grow from $6.29 billion in 2025 to $6.67 billion in 2026, with North America holding the largest share in 2025.

Why it matters: - Acute pancreatitis drives hospital care, imaging, lab testing, procedures and longer stays, which raises treatment demand and healthcare costs. - The market outlook points to expanding need for diagnosis and management as gallstone-related disorders and alcohol use remain major triggers. - The report’s forecast signals where providers, device makers and treatment developers may see growing demand through 2030.

What happened: - The Business Research Company released its Acute Pancreatitis Market Analysis Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the acute pancreatitis market at $6.29 billion in 2025 and $6.67 billion in 2026. - The report projects the market will reach $8.55 billion by 2030. - North America held the largest share of the acute pancreatitis market in 2025. - The analysis includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also says 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis. - A free sample is available here. - The full report is available here.

The details: - The market is expected to grow at a 6.0% compound annual growth rate in the historical period described by the report. - The report forecasts a 6.4% compound annual growth rate through 2030. - The report links historical growth to rising gallstone-related disorders, excessive alcohol use, low public awareness of early symptoms, routine imaging and lab diagnostics, and a growing patient base in hospitals and clinics. - Future growth is tied to targeted therapies, more lifestyle awareness, wider use of minimally invasive procedures, expansion of healthcare facilities and new diagnostic technologies. - The report identifies rising gallstone- and alcohol-induced pancreatitis cases, broader use of advanced imaging and laboratory tests, more intravenous fluids and nutritional support, greater acceptance of ERCP, and stronger early-diagnosis strategies as key trends. - Acute pancreatitis is sudden inflammation and swelling of the pancreas during a brief illness. - Gallstones blocking pancreatic ducts and excessive alcohol consumption are major causes of the condition. - Increased healthcare spending is a major driver of the market. - Acute pancreatitis can cause necrotizing pancreatitis, organ failure and infections, which can require expensive treatment, surgery and extended hospitalization. - The Canadian Institute for Health Information projected Canada’s total health expenditure would reach $344 billion in 2023, up 2.8% from the prior year.

Between the lines: - The market’s growth story is not just about more cases; it also reflects a shift toward earlier diagnosis and more resource-intensive care. - ERCP and advanced imaging matter because they point to more sophisticated treatment pathways, not just broader testing. - The report’s emphasis on healthcare spending suggests reimbursement pressure and hospital resource use are part of the market opportunity. - North America’s lead in 2025 likely reflects established healthcare infrastructure and diagnosis rates, although the report does not break down the drivers by country.

What’s next: - The market is set to expand as health systems adopt more advanced diagnostics and minimally invasive procedures. - Growth will likely track changes in gallstone disease, alcohol-related illness and the pace of healthcare infrastructure expansion. - The report indicates future demand will stay tied to early diagnosis and patient-care strategies rather than a single treatment category.

The bottom line: - Acute pancreatitis is emerging as a growing treatment market, with rising case volume, higher care intensity and broader diagnostic adoption supporting a path toward $8.55 billion by 2030.